VRTX Vertex Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX

Price (delayed)

$495.26

Market cap

$127.8B

P/E Ratio

31.79

Dividend/share

N/A

EPS

$15.58

Enterprise value

$119.37B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The equity has grown by 29% YoY and by 5% from the previous quarter
The EPS has increased by 23% year-on-year and by 11% since the previous quarter
Vertex Pharmaceuticals's quick ratio has decreased by 20% YoY and by 13% QoQ
The price to earnings (P/E) is 17% more than the 5-year quarterly average of 27.1 and 17% more than the last 4 quarters average of 27.1
Sector: Healthcare
Industry: Biotechnology
Website: https://www.vrtx.com/
Peers: GILD ABBV BMY JNJ

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
258.05M
Market cap
$127.8B
Enterprise value
$119.37B
Valuations
Price to earnings (P/E)
31.79
Price to book (P/B)
6.9
Price to sales (P/S)
12.56
EV/EBIT
24.81
EV/EBITDA
23.84
EV/Sales
11.72
Earnings
Revenue
$10.19B
EBIT
$4.81B
EBITDA
$5.01B
Free cash flow
$3.72B
Per share
EPS
$15.58
Free cash flow per share
$14.4
Book value per share
$71.8
Revenue per share
$39.45
TBVPS
$85.18
Balance sheet
Total assets
$23.92B
Total liabilities
$5.37B
Debt
$721.3M
Equity
$18.55B
Working capital
$9.49B
Liquidity
Debt to equity
0.04
Current ratio
3.5
Quick ratio
3.15
Net debt/EBITDA
-1.69
Margins
EBITDA margin
49.2%
Gross margin
86.9%
Net margin
39.5%
Operating margin
40.7%
Efficiency
Return on assets
18.1%
Return on equity
23.6%
Return on invested capital
65.5%
Return on capital employed
23.9%
Return on sales
47.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.61%
1 week
0.75%
1 month
4.49%
1 year
40.73%
YTD
21.72%
QTD
5.66%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$10.19B
Gross profit
$8.85B
Operating income
$4.14B
Net income
$4.02B
Gross margin
86.9%
Net margin
39.5%
Vertex Pharmaceuticals's net income has increased by 23% YoY and by 11% QoQ
VRTX's net margin is up by 12% YoY and by 8% QoQ
VRTX's revenue is up by 11% YoY and by 3.2% QoQ
The operating income has grown by 10% since the previous quarter and by 3.7% year-on-year

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
VRTX P/E details
P/E
31.79
P/B
6.9
P/S
12.56
EV/EBIT
24.81
EV/EBITDA
23.84
EV/Sales
11.72
The EPS has increased by 23% year-on-year and by 11% since the previous quarter
The price to earnings (P/E) is 17% more than the 5-year quarterly average of 27.1 and 17% more than the last 4 quarters average of 27.1
The equity has grown by 29% YoY and by 5% from the previous quarter
The stock's price to book (P/B) is 19% more than its last 4 quarters average of 5.8 and 3% more than its 5-year quarterly average of 6.7
The price to sales (P/S) is 27% more than the 5-year quarterly average of 9.9 and 26% more than the last 4 quarters average of 10.0
VRTX's revenue is up by 11% YoY and by 3.2% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has declined by 32% year-on-year and by 6% since the previous quarter
The return on sales has increased by 5% since the previous quarter and by 3.1% year-on-year
VRTX's return on assets is up by 4.6% since the previous quarter but it is down by 3.7% year-on-year
The return on equity has grown by 4.4% since the previous quarter but it has declined by 3.7% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 26% YoY and by 5% QoQ
Vertex Pharmaceuticals's quick ratio has decreased by 20% YoY and by 13% QoQ
VRTX's debt is 96% lower than its equity
The equity has grown by 29% YoY and by 5% from the previous quarter
The debt to equity fell by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.